F4-neuroprostanes mediate neurological severity in Rett syndrome

Cinzia Signorini, Claudio De Felice, Silvia Leoncini, Anna Giardini, Maurizio D'Esposito, Stefania Filosa, Floriana Della Ragione, Marcello Rossi, Alessandra Pecorelli, Giuseppe Valacchi, Lucia Ciccoli, Joussef Hayek

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Background: Rett syndrome (RTT) is a pervasive development disorder, mainly caused by mutations in the methyl-CpG binding protein 2 (MeCP2) gene. No reliable biochemical markers of the disease are available. Here we assess F4-neuroprostanes (F4-NeuroPs), lipid peroxidation products of the docosahexaenoic acid, as a novel disease marker in RTT and correlate it with clinical presentation, MeCP2 mutation type, and disease progression. In addition, we investigate on the impact of ω-3 polyunsaturated fatty acids (ω-3 PUFAs) supplementation on F4-NeuroPs levels. Methods: A case-control study design was used. A cohort of RTT patients (n=144) exhibiting different clinical presentations, disease stages, and MeCP2 gene mutations were evaluated. F4-NeuroPs were measured in free form using a GC/NICI-MS/MS technique. Plasma F4-NeuroPs levels in patients were compared to healthy controls and related to RTT forms, disease progression, and response to ω-3 PUFAs supplementation. Results: Plasma F4-NeuroPs levels were i) higher in RTT than in controls; ii) increased with the severity of neurological symptoms; iii) significantly elevated during the typical disease progression; iv) higher in MeCP2-nonsense as compared to missense mutation carriers; v) higher in typical RTT as compared to RTT variants; and vi) decreased in response to 12months ω-3 PUFAs oral supplementation. Conclusions: Quantification of plasma F4-NeuroPs provides a novel RTT marker, related to neurological symptoms severity, mutation type and clinical presentation.

Original languageEnglish
Pages (from-to)1399-1406
Number of pages8
JournalClinica Chimica Acta
Volume412
Issue number15-16
DOIs
Publication statusPublished - Jul 15 2011

Fingerprint

Neuroprostanes
Rett Syndrome
Methyl-CpG-Binding Protein 2
Plasmas
Disease Progression
Mutation
Genes
Docosahexaenoic Acids
Unsaturated Fatty Acids
Pervasive Child Development Disorders
Missense Mutation
Lipid Peroxidation
Lipids
Case-Control Studies
Biomarkers

Keywords

  • ω-3 polyunsaturated fatty acids
  • Autism spectrum disorders
  • CDKL5
  • MeCP2
  • Neuroprostanes
  • Rett syndrome

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Biochemistry, medical
  • Medicine(all)

Cite this

Signorini, C., De Felice, C., Leoncini, S., Giardini, A., D'Esposito, M., Filosa, S., ... Hayek, J. (2011). F4-neuroprostanes mediate neurological severity in Rett syndrome. Clinica Chimica Acta, 412(15-16), 1399-1406. https://doi.org/10.1016/j.cca.2011.04.016

F4-neuroprostanes mediate neurological severity in Rett syndrome. / Signorini, Cinzia; De Felice, Claudio; Leoncini, Silvia; Giardini, Anna; D'Esposito, Maurizio; Filosa, Stefania; Della Ragione, Floriana; Rossi, Marcello; Pecorelli, Alessandra; Valacchi, Giuseppe; Ciccoli, Lucia; Hayek, Joussef.

In: Clinica Chimica Acta, Vol. 412, No. 15-16, 15.07.2011, p. 1399-1406.

Research output: Contribution to journalArticle

Signorini, C, De Felice, C, Leoncini, S, Giardini, A, D'Esposito, M, Filosa, S, Della Ragione, F, Rossi, M, Pecorelli, A, Valacchi, G, Ciccoli, L & Hayek, J 2011, 'F4-neuroprostanes mediate neurological severity in Rett syndrome', Clinica Chimica Acta, vol. 412, no. 15-16, pp. 1399-1406. https://doi.org/10.1016/j.cca.2011.04.016
Signorini, Cinzia ; De Felice, Claudio ; Leoncini, Silvia ; Giardini, Anna ; D'Esposito, Maurizio ; Filosa, Stefania ; Della Ragione, Floriana ; Rossi, Marcello ; Pecorelli, Alessandra ; Valacchi, Giuseppe ; Ciccoli, Lucia ; Hayek, Joussef. / F4-neuroprostanes mediate neurological severity in Rett syndrome. In: Clinica Chimica Acta. 2011 ; Vol. 412, No. 15-16. pp. 1399-1406.
@article{24691e7a5f604920b85d68dcfb44701e,
title = "F4-neuroprostanes mediate neurological severity in Rett syndrome",
abstract = "Background: Rett syndrome (RTT) is a pervasive development disorder, mainly caused by mutations in the methyl-CpG binding protein 2 (MeCP2) gene. No reliable biochemical markers of the disease are available. Here we assess F4-neuroprostanes (F4-NeuroPs), lipid peroxidation products of the docosahexaenoic acid, as a novel disease marker in RTT and correlate it with clinical presentation, MeCP2 mutation type, and disease progression. In addition, we investigate on the impact of ω-3 polyunsaturated fatty acids (ω-3 PUFAs) supplementation on F4-NeuroPs levels. Methods: A case-control study design was used. A cohort of RTT patients (n=144) exhibiting different clinical presentations, disease stages, and MeCP2 gene mutations were evaluated. F4-NeuroPs were measured in free form using a GC/NICI-MS/MS technique. Plasma F4-NeuroPs levels in patients were compared to healthy controls and related to RTT forms, disease progression, and response to ω-3 PUFAs supplementation. Results: Plasma F4-NeuroPs levels were i) higher in RTT than in controls; ii) increased with the severity of neurological symptoms; iii) significantly elevated during the typical disease progression; iv) higher in MeCP2-nonsense as compared to missense mutation carriers; v) higher in typical RTT as compared to RTT variants; and vi) decreased in response to 12months ω-3 PUFAs oral supplementation. Conclusions: Quantification of plasma F4-NeuroPs provides a novel RTT marker, related to neurological symptoms severity, mutation type and clinical presentation.",
keywords = "ω-3 polyunsaturated fatty acids, Autism spectrum disorders, CDKL5, MeCP2, Neuroprostanes, Rett syndrome",
author = "Cinzia Signorini and {De Felice}, Claudio and Silvia Leoncini and Anna Giardini and Maurizio D'Esposito and Stefania Filosa and {Della Ragione}, Floriana and Marcello Rossi and Alessandra Pecorelli and Giuseppe Valacchi and Lucia Ciccoli and Joussef Hayek",
year = "2011",
month = "7",
day = "15",
doi = "10.1016/j.cca.2011.04.016",
language = "English",
volume = "412",
pages = "1399--1406",
journal = "Clinica Chimica Acta",
issn = "0009-8981",
publisher = "Elsevier",
number = "15-16",

}

TY - JOUR

T1 - F4-neuroprostanes mediate neurological severity in Rett syndrome

AU - Signorini, Cinzia

AU - De Felice, Claudio

AU - Leoncini, Silvia

AU - Giardini, Anna

AU - D'Esposito, Maurizio

AU - Filosa, Stefania

AU - Della Ragione, Floriana

AU - Rossi, Marcello

AU - Pecorelli, Alessandra

AU - Valacchi, Giuseppe

AU - Ciccoli, Lucia

AU - Hayek, Joussef

PY - 2011/7/15

Y1 - 2011/7/15

N2 - Background: Rett syndrome (RTT) is a pervasive development disorder, mainly caused by mutations in the methyl-CpG binding protein 2 (MeCP2) gene. No reliable biochemical markers of the disease are available. Here we assess F4-neuroprostanes (F4-NeuroPs), lipid peroxidation products of the docosahexaenoic acid, as a novel disease marker in RTT and correlate it with clinical presentation, MeCP2 mutation type, and disease progression. In addition, we investigate on the impact of ω-3 polyunsaturated fatty acids (ω-3 PUFAs) supplementation on F4-NeuroPs levels. Methods: A case-control study design was used. A cohort of RTT patients (n=144) exhibiting different clinical presentations, disease stages, and MeCP2 gene mutations were evaluated. F4-NeuroPs were measured in free form using a GC/NICI-MS/MS technique. Plasma F4-NeuroPs levels in patients were compared to healthy controls and related to RTT forms, disease progression, and response to ω-3 PUFAs supplementation. Results: Plasma F4-NeuroPs levels were i) higher in RTT than in controls; ii) increased with the severity of neurological symptoms; iii) significantly elevated during the typical disease progression; iv) higher in MeCP2-nonsense as compared to missense mutation carriers; v) higher in typical RTT as compared to RTT variants; and vi) decreased in response to 12months ω-3 PUFAs oral supplementation. Conclusions: Quantification of plasma F4-NeuroPs provides a novel RTT marker, related to neurological symptoms severity, mutation type and clinical presentation.

AB - Background: Rett syndrome (RTT) is a pervasive development disorder, mainly caused by mutations in the methyl-CpG binding protein 2 (MeCP2) gene. No reliable biochemical markers of the disease are available. Here we assess F4-neuroprostanes (F4-NeuroPs), lipid peroxidation products of the docosahexaenoic acid, as a novel disease marker in RTT and correlate it with clinical presentation, MeCP2 mutation type, and disease progression. In addition, we investigate on the impact of ω-3 polyunsaturated fatty acids (ω-3 PUFAs) supplementation on F4-NeuroPs levels. Methods: A case-control study design was used. A cohort of RTT patients (n=144) exhibiting different clinical presentations, disease stages, and MeCP2 gene mutations were evaluated. F4-NeuroPs were measured in free form using a GC/NICI-MS/MS technique. Plasma F4-NeuroPs levels in patients were compared to healthy controls and related to RTT forms, disease progression, and response to ω-3 PUFAs supplementation. Results: Plasma F4-NeuroPs levels were i) higher in RTT than in controls; ii) increased with the severity of neurological symptoms; iii) significantly elevated during the typical disease progression; iv) higher in MeCP2-nonsense as compared to missense mutation carriers; v) higher in typical RTT as compared to RTT variants; and vi) decreased in response to 12months ω-3 PUFAs oral supplementation. Conclusions: Quantification of plasma F4-NeuroPs provides a novel RTT marker, related to neurological symptoms severity, mutation type and clinical presentation.

KW - ω-3 polyunsaturated fatty acids

KW - Autism spectrum disorders

KW - CDKL5

KW - MeCP2

KW - Neuroprostanes

KW - Rett syndrome

UR - http://www.scopus.com/inward/record.url?scp=79956316620&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79956316620&partnerID=8YFLogxK

U2 - 10.1016/j.cca.2011.04.016

DO - 10.1016/j.cca.2011.04.016

M3 - Article

VL - 412

SP - 1399

EP - 1406

JO - Clinica Chimica Acta

JF - Clinica Chimica Acta

SN - 0009-8981

IS - 15-16

ER -